PTPN1 and obesity due to melanocortin 4 receptor deficiency: Consequently, inhibiting of PTP1B was considered to be a potential therapeutics for treating Type 2 diabetes and obesity by enhance insulin sensitivity and resistance to obesity [5,6,7,8].